Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma

Ting Wang; Laura M. Fox; Desuo Wang

doi:10.1016/j.jchromb.2005.10.009

Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma

Ting Wang
, Laura M. Fox
, Desuo Wang

Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

MS23 is a vasodilator with unique dual action pharmacological profile to inhibit type 4 PDE and antagonize L-type calcium channels. We validated an analytical protocol for MS23 in rat plasma using high performance liquid chromatography (HPLC). A C18 column and a phosphate/acetonitrite buffer were used for chromatographic separation. UV detection was performed at 307 nm. The calibration curve for MS23 was linear in the range from 50 to 10,000 ng/ml. The limit of quantification (LOQ) was 50 ng/ml. The results demonstrate that the method has linearity (R = 0.9989), specificity, and acceptable precision/accuracy. This method is simple, economic, and sufficient for in vivo pharmacokinetic studies on the compound.

Original language	English (US)
Pages (from-to)	13-17
Number of pages	5
Journal	Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume	830
Issue number	1
DOIs	https://doi.org/10.1016/j.jchromb.2005.10.009
State	Published - Jan 2 2006

Keywords

Antihypertensive
Calcium channel antagonist
Dual action
MS23
PDE4 inhibitor
Validation

ASJC Scopus subject areas

Analytical Chemistry
Biochemistry
Clinical Biochemistry
Cell Biology

Access to Document

10.1016/j.jchromb.2005.10.009

Cite this

@article{254954494cdd4bb1876fc6121c3a19a8,

title = "Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma",

abstract = "MS23 is a vasodilator with unique dual action pharmacological profile to inhibit type 4 PDE and antagonize L-type calcium channels. We validated an analytical protocol for MS23 in rat plasma using high performance liquid chromatography (HPLC). A C18 column and a phosphate/acetonitrite buffer were used for chromatographic separation. UV detection was performed at 307 nm. The calibration curve for MS23 was linear in the range from 50 to 10,000 ng/ml. The limit of quantification (LOQ) was 50 ng/ml. The results demonstrate that the method has linearity (R = 0.9989), specificity, and acceptable precision/accuracy. This method is simple, economic, and sufficient for in vivo pharmacokinetic studies on the compound.",

keywords = "Antihypertensive, Calcium channel antagonist, Dual action, MS23, PDE4 inhibitor, Validation",

author = "Ting Wang and Fox, \{Laura M.\} and Desuo Wang",

year = "2006",

month = jan,

day = "2",

doi = "10.1016/j.jchromb.2005.10.009",

language = "English (US)",

volume = "830",

pages = "13--17",

journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",

issn = "1570-0232",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma

AU - Wang, Ting

AU - Fox, Laura M.

AU - Wang, Desuo

PY - 2006/1/2

Y1 - 2006/1/2

N2 - MS23 is a vasodilator with unique dual action pharmacological profile to inhibit type 4 PDE and antagonize L-type calcium channels. We validated an analytical protocol for MS23 in rat plasma using high performance liquid chromatography (HPLC). A C18 column and a phosphate/acetonitrite buffer were used for chromatographic separation. UV detection was performed at 307 nm. The calibration curve for MS23 was linear in the range from 50 to 10,000 ng/ml. The limit of quantification (LOQ) was 50 ng/ml. The results demonstrate that the method has linearity (R = 0.9989), specificity, and acceptable precision/accuracy. This method is simple, economic, and sufficient for in vivo pharmacokinetic studies on the compound.

AB - MS23 is a vasodilator with unique dual action pharmacological profile to inhibit type 4 PDE and antagonize L-type calcium channels. We validated an analytical protocol for MS23 in rat plasma using high performance liquid chromatography (HPLC). A C18 column and a phosphate/acetonitrite buffer were used for chromatographic separation. UV detection was performed at 307 nm. The calibration curve for MS23 was linear in the range from 50 to 10,000 ng/ml. The limit of quantification (LOQ) was 50 ng/ml. The results demonstrate that the method has linearity (R = 0.9989), specificity, and acceptable precision/accuracy. This method is simple, economic, and sufficient for in vivo pharmacokinetic studies on the compound.

KW - Antihypertensive

KW - Calcium channel antagonist

KW - Dual action

KW - MS23

KW - PDE4 inhibitor

KW - Validation

UR - https://www.scopus.com/pages/publications/29244470474

UR - https://www.scopus.com/pages/publications/29244470474#tab=citedBy

U2 - 10.1016/j.jchromb.2005.10.009

DO - 10.1016/j.jchromb.2005.10.009

M3 - Article

C2 - 16257589

AN - SCOPUS:29244470474

SN - 1570-0232

VL - 830

SP - 13

EP - 17

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

IS - 1

ER -

Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this